Investigational drug · Phase 3
TQB3473
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Primary Immune Thrombocytopenia.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 24, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "TQB3473"
First trial start
2025
Apr 30, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TQB3473", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary Immune Thrombocytopenia
Approved drugs for the same conditions: Immune thrombocytopenia · Hematology and blood cancers · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "TQB3473" as an intervention, largest first.
- A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in AdultsNot yet recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07083739 · 320 participants (planned) · Start Aug 2025 · Primary completion Sep 2027
Drug: TQB3473 Tablets · For: Primary Immune Thrombocytopenia
Sites: Hefei, China; Wuhu, China; Beijing, China · 51 sites in all
- A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune ThrombocytopeniaPivotal-lookingRecruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06900920 · 199 participants (planned) · Start Apr 30, 2025 · Primary completion Mar 2027
Drug: TQB3473 Tablets; TQB3473 Placebo · For: Primary Immune Thrombocytopenia
Sites: Hefei, China; Wuhu, China; Beijing, China · 53 sites in all
- A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological MalignanciesStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT04412577 · 57 participants (planned) · Start Oct 12, 2020 · Primary completion Dec 2021
Drug: TQB3473 · For: Relapsed/Refractory Hematological Malignancies
Sites: Zhengzhou, China; Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Relapsed/refractory immune thrombocytopenia-moving past the toxicity profile of spleen tyrosine kinase inhibitors with TQB3473.
Shah S · J Thromb Haemost 2026
- TQB3473, a novel spleen tyrosine kinase inhibitor for primary immune thrombocytopenia: a single-arm, open-label, multicenter phase 1 study.
Ding B, Gong T, Du X, et al. · J Thromb Haemost 2026
Also in development for Primary Immune Thrombocytopenia
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- CM336group, QiShen YiQi Dripping Pills 3 bagsPhase 37 trials
Keymed Biosciences Co.Ltd · Multiple Myeloma (MM), Primary Light-Chain Amyloidosis, Primary Immune Thrombocytopenia
- CM313Phase 36 trials
Keymed Biosciences Co.Ltd · Systemic Lupus Erythematosus, Primary Immune Thrombocytopenia, Platelet Transfusion Refractoriness
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.